Spero Therapeutics (SPRO) Stock: Buy, Sell, or Hold?
SPRO - Spero Therapeutics, Inc. Common Stock
$1.11
-0.02 (-1.77%)
▼
5d:
+0.91%
30d:
-11.2%
90d:
-5.93%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When SPRO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SPRO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SPRO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SPRO is currently trading at $1.11, which is considered oversold relative to its 30-day fair value range of $1.12 to $1.23. From a valuation perspective, the stock is trading at a discount (Forward PE: -10.6) compared to its historical average (6.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SPRO is in a strong downtrend. The price is currently testing key support at $1.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $5.00 (+350.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRO is in a strong downtrend. The price is currently testing key support at $1.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $5.00 (+350.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.12 -
$1.23
Company Quality Score
43/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
68.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 350.5% below Wall St target ($5.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.12 -
$1.23
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.60
(54.2%)
Support & Resistance Levels
Support Level
$1.09
Resistance Level
$1.24
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.57
Wall Street Target
$5.00
(+350.5%)
Revenue Growth (YoY)
-95.6%
Earnings Growth (YoY)
75.3%
Profit Margin
15.7%
PE vs Historical
-10.6 vs 6.5
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 8:07 PM ET
Data refreshes hourly during market hours. Next update: 9:07 PM
Data refreshes hourly during market hours. Next update: 9:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
